What is Claimed:

1. Use of an isolated peptide for the preparation of a medicament for the inhibition of angiogenesis in a patient in need, wherein the peptide comprises the amino acid sequence of KFARLWTEIPTAIT (SEQ ID NO: 1), FTEIPTI (SEQ ID NO: 3) or a fragments thereof.

2. The use of claim 1 where the patient is suffering from a disorder associated with VEGF-induced permeability or cancer.

3. Use of an isolated peptide for the preparation of a medicament for the treatment of a disorder associated with VEGF-induced vascular permeability wherein the isolated peptide comprises the amino acid sequence of KFARLWTEIPTAIT (SEQ ID NO: 1), FTEIPTI (SEQ ID NO: 3) or a fragments thereof.

4. The use of claim 3 wherein the VEGF associated vascular disorder is visual impairment or vision loss (blindness), macular degeneration, central retinal vein occlusion, branch retinal venin occlusion proliferative diabetic retinopathy, neovascular age-related macular degeneration (AMD), retinopathy of prematurity, ischemic retinopathy, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retina ischemia, diabetic retinal edema, and proliferative diabetic retinopathy, rubeosis iridis, neovascular glaucoma, retinoblastoma, uveitis and corneal graft neovascularization.

5. The use of any one of claims 1-4 wherein the peptide is linked to a carrier peptide.

6. The use of claim 5 wherein the carrier peptide is antennapedia peptide (AP), antennapedia peptide, penetratin peptide, TAT, tranportan or polyarginine.

7. The use of claim any one of claims 1-6, wherein the peptide is conjugated to a fatty acid.

8. The use of claim 7, wherein the peptide is myristoylated.

9. The use of any one of claims 1-8, wherein the isolated peptide or a fragment thereof is to be administered in combination with one or more VEGF inhibitors.

10. The use of any one of claims 1-8, wherein the isolated peptide or fragment thereof is to be administered in combination with laser treatment of eye disease.

11. The use of any one of claims 1-8, wherein the isolated peptide or fragment thereof is to be administered in combination with a steroid.

12. The use of any one of claims 1-11, wherein the isolated peptide, VEGF inhibitor or steroid is to be delivered via intravitreal injection or topically.

13. An isolated peptide for use in the inhibition of angiogenesis, wherein the peptide comprises the amino acid sequence of KFARLWTEIPTAIT (SEQ ID NO: 1), FTEIPTI (SEQ ID NO: 3) or a fragments thereof.

14. The peptide of claim 13 for use in inhibition of angiogenesis in a patient suffering from a disorder associated with VEGF-induced vascular permeability.

15. An isolated peptide for use in the treatment of a disorder associated with VEGF-induced vascular permeability.

16. The peptide of claim 14 or 15, wherein the disorder associated with VEGF-induced vascular permeability is visual impairment or vision loss (blindness), macular degeneration, central retinal vein occlusion, branch retinal venin occlusion proliferative diabetic retinopathy, neovascular age-related macular degeneration (AMD), retinopathy of prematurity, ischemic retinopathy, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retina ischemia, diabetic retinal edema, and proliferative diabetic retinopathy, rubeosis iridis, neovascular glaucoma, retinoblastoma, uveitis and corneal graft neovascularization.

17. The peptide of any one of claims 13-16, wherein the peptide is linked to a carrier peptide.

18. The peptide of claim 17, wherein the carrier peptide is antennapedia peptide (AP), penetratin peptide, TAT, tranportan or polyarginine.

19. The peptide of any one of claims 13-18, wherein the peptide is conjugated to a fatty acid.

20. The peptide of claim 19, wherein the peptide is myristoylated.

21. The peptide of any one of claims 13-20, wherein the isolated peptide or fragment thereof is to be administered in combination with one or more VEGF inhibitors.

22. The peptide of any one of claims 13-21, wherein the isolated peptide or fragment thereof is to be administered in combination with laser treatment of eye disease.

23. The peptide of any one of claims 13-21, wherein the isolated peptide or fragment thereof is to be administered in combination with a steroid.

24. The peptide of any one of claims 13-23, wherein the isolated peptide, VEGF inhibitor or steroid is to be administered by intravitreal injection or topically.